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A 2gtl 1 clone encoding prostate specific antigen has been isolated from a human prostate cDNA library. 
The cDNA insert of 1415 nucleotides hybridizes pecifically to a prostate mRNA species of 1.5 kb. The 
nucleotide sequence codes for part of a signal peptide, ashort propiece and the mature protein of 237 amino 
acid residues. The Mr for the non-glycosylated protein was 26 089. One potential site for N-linked carbohy- 
drate attachment was identified. The primary structure shows extensive homology with proteases of the kal- 
likrein family. 
cDNA clone; cDNA library; Kallikrein-like; (Human prostate) 
1. INTRODUCTION 
The digestive nzymes trypsin and chymotrypsin 
are among the best characterized proteins. Their 
structures have become the model for several 
related proteolytic enzymes that constitute the 
superfamily of serine proteases. In this group of 
proteins are found enzymes of such diverging 
specificity as collagenase, elastase and the highly 
specific enzymes of the complement and coagula- 
tion systems. Characteristic of the serine proteases 
are the active-site amino acid residues His, Asp 
and Ser. The substrate specificity is mainly deter- 
mined by the unique microenvironment provided 
by the amino acid residues lining the enzymes' 
catalytic pockets. 
The glandular kallikreins constitute a subfamily 
of the serine proteases, originally identified by the 
ability of the proteases to release kinins from high- 
Mr substrates (review [1]). More recently, proteases 
such as the epidermal growth factor-binding pro- 
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tein [2] and the y-subunit of the 7 S nerve growth 
factor complex [3] have been included in the 
category due to their high degree of sequence 
homology to pancreatic kallikrein. The glandular 
kallikreins have been most intensively studied in 
the mouse, where 25-30 genes are concentrated to
a locus on chromosome 7 [4]. There are also 
several kallikrein genes in the rat [5]. Recently, by 
means of low-stringency hybridization to a pan- 
creatic kallikrein cDNA probe, it was shown that 
the human genome also contains everal kallikrein 
genes [6]. 
Human prostate specific antigen (PSA) is a 
kaIlikrein-like protease [7] present in seminal 
plasma at a concentration of 0.7 mg/ml [8]. It is a 
single-chain glycoprotein of Mr -33000 [8]. 
Although the biological function of the enzyme 
has yet to be fully determined, recent experiments 
have shown it to be involved in the liquefaction of 
seminal coagulum by proteolysis of its predomi- 
nant protein component - a high-Mr seminal vesi- 
cle protein (HMW-SV-protein) or semenogelin 
[7,9]. The primary structure of PSA was recently 
determined, confirming its likeness to kallikrein 
[10]. Here we present he molecular cloning of a 
PSA encoding cDNA. 
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2. MATERIALS AND METHODS 
2.1. Construction of the cDNA fibrary 
Human prostate tissue was obtained from pa- 
tients undergoing surgical treatment for benign 
prostatic hyperplasia. RNA was purified from the 
prostate tissue by the guanidine thiocyanate 
method of Chirgwin et al. [11]. The mRNA frac- 
tion was recovered by two passages of total RNA 
on oligo(dT)-cellulose (Pharmacia). 
Single-stranded cDNA was synthesized from 
10/zg mRNA with 75 units AMV reverse transcrip- 
tase (Boehringer-Mannheim), following the pro- 
tocol of Maniatis et al. [12]. Second strand 
synthesis was done with DNA polymerase 
(Boehringer-Mannheim), RNase H (Pharmacia) 
and E. coli DNA ligase (New England Biolabs), ac- 
cording to Gubler and Hoffman [13]. Excess 
nucleotides were removed by ethanol precipitation 
from 2 M ammonium acetate. The recovered s- 
cDNA (520 ng) was methylated with 28 units 
EcoRI methylase (New England Biolab) in 80/zM 
S-adenosylmethionine (Sigma) containing buffer 
(0.1 M Tris-HCl, 10 mM EDTA, pH 8). Linkers 
were added to the cDNA by overnight incubation 
with 1/~g EcoRI linker (Pharmacia) and 5 units T4 
DNA ligase (Amersham) at 12°C. Following 
phenol/chloroform and chloroform extractions 
and precipitation from 2 M ammonium acetate, 
the resolubilized cDNA was digested with 250 units 
EcoRI for 3 h. The digested material was size- 
selected on a 0.6 × 21 cm column of Sepharose 
CL-4B, run in 10 mM Tris-HCl, pH 8.0, 0.3 M 
NaC1 and 1 mM EDTA. The material from the 
break-through fraction, approx. 140 ng cDNA, 
was ligated into 14/~g EcoRI-digested and 
phosphatased )~gtl 1 DNA. One-third of the ligated 
material was packed in vitro using a commercial 
extract (Promega Biotecniques). 
2.2. Isolation and analysis of  cDNA clones 
A rabbit antiserum raised against PSA purified 
from pooled human seminal plasma has been 
described previously [7]. Antibodies were affinity- 
purified on a column with PSA immobilized to 
Sepharose 4B, following standard methods. 
Recombinant phages were screened with the 
affinity-purified antibodies on duplicate 
nitrocellulose filters, using a modified procedure 
of Young and Davies [14,15]. Immunoreacted an- 
tibodies were detected with a commercial alkaline 
phosphatase-conjugated second antibody (Pro- 
mega Biotecniques), following the manufacturer's 
recommendations. Recombinant phages were 
prepared by the plate lysate method and subse- 
quent banding in a CsCI gradient. Approx. 400 gg 
phage DNA, readily digestable by restriction en- 
zymes, was obtained from five 'large' (13 cm 
diameter) plates. The cDNA inserts were sub- 
cloned into the EcoRI site of the plasmid vector, 
pUC18. Plasmid preparations were done by the 
alkaline lysis method in [12]. Nucleotide sequences 
were determined with the modified dideoxy chain 
terminator method of Biggin et al. [16] on 
subclones in bacteriophage M13 rap8, generated 
from sonicated material as described by Bankier 
and Barrell [17]. The nucleotide sequences were 
computed with programmes described by Staden 
[18,191. 
2.3. Miscellaneous 
RNA was analysed by electrophoresis in 1.3% 
agarose gels containing formamide and blotted on- 
to nitrocellulose paper as described [20,21]. Nick 
translation was done with a commercial kit from 
Amersham, and following the manufacturer's 
recommendations. Hybridizations were done with 
5 x 106 cpm nick-translated DNA per ml at 42°C 
for 16 h in 50 mM sodium phosphate, pH 7.4, 
0.75 M NaCI, 0.1% SDS, 0.05% (w/v) sodium 
pyrophosphate and 100/zg/ml of herring sperm 
DNA. Excess radioactivity was washed away by 
several changes of 30 mM sodium citrate, pH 7.0, 
containing 0.3 M NaCI and 0.05% (w/v) 
pyrophosphate at room temperature, and then in 
7.5 mM sodium citrate and 75 mM NaCI at 68°C 
for 0.5 h. The filters were exposed to Kodak X- 
AR-5 film between enhancer screens at -70°C.  
3. RESULTS 
3.1. Isolation of the cDNA clone 
A human prostate cDNA library with 3 x l0 s 
members was constructed in bacteriophage ,~gtl 1. 
Affinity-purified antibodies to human PSA were 
used to screen 50000 recombinants of the library 
by a modified Young and Davies procedure. One 
clone producing recombinant PSA was identified. 
The clone, designated AHPSA-1, was isolated and 
the DNA analysed. By agarose gel electrophoresis 
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Fig.l. Northern blot. 20/zg prostate RNA was 
electrophoresed in a 20 cm agarose gel containing 
formaldehyde. The material was blotted onto 
nitrocellulose filter and probed with nick-translated 
cDNA from AHPSA-1. The arrows indicate the origin of 
electrophoresis and the positions of 28 S and 18 S RNA. 
of  an EcoRI digest, the size of  the cDNA insert was 
estimated to be approx. 1.5 kb. A labelled probe 
was prepared by nick translation of  the cDNA.  
Upon Northern blot analysis of  total prostate 
RNA,  this probe hybridized specifically to a 
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Fig.2. Nucleotide and derived amino acid sequence of a 
cDNA encoding human prostate specific antigen. Amino 
acid numbering starts with residue 1 of the mature 
protein. The arrow denotes the suggested cleavage site 
for signal peptidase. The active site amino acid residues 
are boxed. Position for possible N-linked carbohydrate 
attachment is indicated by the lozenge. The 
polyadenylation signal is underlined. 
CTSTCCTGGAGGCACTGGGAAGCCTAGAGAAGGCTGTGAGCCAAGGAGGGAGGGTCTTCC 
1210 1220 1230 1240 1250 1260 
TTTQQCATGGGATGGGGATGAAGTAAGC~GAGGGACTGGACCCCCTQC~GCTGATTCAC 
1270 1280 1290 1300 1310 1320 
TATGGGGGGA6CPFGTATTC~GTCCTCCAGAC~CCCTCAGAGTTTGATC~GTTTCCTAG 
1330 1340 1950 1360 1370 1380 
TAGAACTCACAGA~w~T~,~AQAGCTQTTATACTGTGaaaaaaaaaaaaaaaaaaaaaaoaa 
1390 1~00 1410 
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message of approx. 1.5 kb (fig.l). It was therefore 
concluded that AHPSA-1 carried an almost full- 
length cDNA insert. The labelled fragment was 
also used to rescreen 16000 recombinants of the 
library. 36 of these hybridized to the probe, and 
thus approx. 0.2% of the prostate mRNA encodes 
PSA. 
3.2. Human prostate specific antigen cDNA 
sequence 
The structure of the cDNA insert in AHPSA-1 
was determined by sequencing 48 random 
subclones in M13 rap8. Each nucleotide was deter- 
mined on average 3.96 times. The sequence of the 
insert is shown in fig.2. The length is 1415 
nucleotides plus a poly(A) tail of undetermined 
size. An open reading frame encodes 257 amino 
acid residues. The amino acid sequence of PSA is 
coded for by nucleotides starting at position 62 to 
a stop codon, TGA, at position 773-775. The 
active-site amino acid residues were identified, 
confirming the serine esterase nature of the protein 
(fig.2). One potential site for N-glycosylation was 
identified at amino acid residue 45. The polypep- 
tide chain of PSA consists of 237 amino acid 
residues and the Mr of the unglycosylated protein 
is 26089. In the 5'-end, the cDNA codes for a 
signal peptide and a short propiece. These residues 
were identified by their homology with other 
members of the kallikrein family and with tryp- 
sinogen [2-4,6,22]. At the 3'-side of the stop 
codon are 640 non-translated nucleotides, follow- 
ed by a poly(A) tail. A polyadenylation signal, 
AATAAA, is located 16 nucleotides upstream 
from the poly(A). Interestingly, there is also a 
putative polyadenylation signal, AGTAAA, 
located at position 800-806. This is the same signal 
and the same location as for the polyadenylation 
signal of human pancreatic kallikrein [6]. 
However, with Northern blot analysis we were 
unable to detect an mRNA of a size around 1.0 kb, 
so the proximal polyadenylation signal is probably 
not used. 
4. DISCUSSION 
PSA has been identified as one of the predomi- 
nant proteins ecreted by the human prostate gland 
[9]. The abundance of messages encoding PSA in 
prostatic mRNA is consistent with this finding. It 
has previously been reported that PSA is strongly 
homologous to members of the glandular 
kallikrein family [7,10]. Comparison of the PSA 
amino acid sequence with that of other serine pro- 
teases confirms this. The highest degree of 
homology is obtained with human pancreatic 
kallikrein (62%0), 7-NGF (55%) and EGF-BP 
(53%), while the figures for bovine trypsin and 
chymotrypsin are 41 and 36%. That it is a member 
of the glandular kallikrein family is further con- 
firmed by the finding that PSA is synthesized with 
a leader peptide that is highly conserved among 
kallikreins. It can in fact be predicted that the 
mRNA encodes an initiator methionine plus three 
more hydrophobic amino acid residues that are not 
represented in the cDNA clone. 
Trypsinogen is converted to ~'-trypsin by a 
specific cleavage of the peptide bond between Lys6 
and IIev [23]. A similar zymogen activation also 
takes place with the kallikreins. Urinary pro- 
kallikrein is activated to kallikrein through specific 
cleavage of the peptide bond between Arg7 and lles 
[24,25]. We suggest that PSA is converted from an 
inactive proform to an active enzyme by a similar 
mechanism. From the homology with human 
urinary prokallikrein [25], we also think it likely 
that the amino-terminal mino acid residue of Pro- 
PSA is Ala_7. 
Several of the glandular kallikreins cleave at the 
carboxy-terminal side of a Lys or Arg residue. 
That is because they have an Asp residue at the 
bottom of the catalytic pocket, capable of attrac- 
ting the positively charged side chains elec- 
trostatically [26]. In PSA, this position is occupied 
by Serls3 which is equivalent to Serls9 in 
chymotrypsinogen. The Gly and Ser residues in 
positions 208 and 219 have small side chains, and 
thus allow access to the catalytic pocket of amino 
acid residues with bulky side chains [26]. It was 
reported recently from studies with synthetic 
substrates that PSA had no detectable activity 
against N~-benzoyl-L-tyrosine ethyl ester, but in- 
stead had activity against Arg/Lys containing 
substrates [7]. The activity was low with all 
substrates tested and did not exclude a restricted 
chymotryptic activity. Indeed, elsewhere it has 
been reported that PSA displays low but detectable 
activity towards chymotryptic substrates [10]. The 
predominant protein in the seminal gel structure 
(semenogelin) is cleaved by PSA during liquefac- 
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tion of semen. Peptides that are degradation 
products of semenogelin have been isolated from 
liquefied semen, and the primary structure has 
been determined for one fragment [27]. The 
carboxy-terminal mino acid residue was reported 
to be tyrosine, a residue that is typically recognized 
by chymotrypsin. 
Recently the primary structure of human PSA 
was determined by Watt et al. [10], using protein 
chemical methods. The sequence presented here is 
deduced from a cDNA clone. Therefore, the 
cDNA might express a rare genetic variant, while 
only the commonest variants are to be expected in 
the protein from pooled seminal plasma. The dif- 
ference at position 70, where the cDNA encodes 
His but Watt et al. report Thr, might thus be ex- 
plained by point mutation. There is another 
disagreement at amino acid residue 151, where 
Watt et al. report Gln; the cDNA encodes Asp at 
this position, and Asp was also identified at this 
position by Edman degradation of a proteolytic 
fragment present in PSA preparations from 
seminal plasma. The amino-terminal sequence of 
the fragment was Lys, Leu, Gin, Cys, Val, Asp, 
Leu, His (Lilja, H., unpublished). However, the 
differences starting at position 141 where the 
cDNA encodes Phe, Leu, Thr and Pro, while Watt 
et al. report His, Leu, Leu, Tyr, Asp, Gin and 
Met, are probably too extensive to be explained by 
point mutations. Although the sequence difference 
might reflect an allelic variation, we find it more 
likely that it is caused by either two non-allelic 
variants, as has been reported for trypsinogen [22] 
or the occurrence of two forms of PSA due to 
alternative splicing of a single primary transcript. 
These questions will probably be answered by fur- 
ther study of the gene structure and biosynthesis of 
PSA. 
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